Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Mallinckrodt
McKesson
Express Scripts
Colorcon

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

FIASP Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Fiasp patents expire, and when can generic versions of Fiasp launch?

Fiasp is a drug marketed by Novo and is included in one NDA. There are eighteen patents protecting this drug.

This drug has thirty patent family members in eighteen countries.

The generic ingredient in FIASP is insulin aspart. There are forty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the insulin aspart profile page.

Summary for FIASP
Drug patent expirations by year for FIASP
Drug Prices for FIASP

See drug prices for FIASP

Pharmacology for FIASP
Drug ClassInsulin Analog
Synonyms for FIASP
1024611-56-0
116094-23-6
139532-40-4
D933668QVX
INA-X14
Insulin aspart
Insulin aspart [USAN:INN:BAN]
NN1218
Novolog Flexpen
Novolog Innolet
Novolog Penfill
NovoMix
UNII-D933668QVX

US Patents and Regulatory Information for FIASP

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novo FIASP insulin aspart SOLUTION;INTRAVENOUS, SUBCUTANEOUS 208751-001 Sep 29, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Novo FIASP FLEXTOUCH insulin aspart SOLUTION;SUBCUTANEOUS 208751-002 Sep 29, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Novo FIASP FLEXTOUCH insulin aspart SOLUTION;SUBCUTANEOUS 208751-002 Sep 29, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for FIASP

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0885961 05C0009 France   Start Trial PRODUCT NAME: INSULINE GLULISINE; REGISTRATION NO/DATE IN FRANCE: EU/1/04/258/001 DU 20040927; REGISTRATION NO/DATE AT EEC: EU/1/04/285/001 DU 20040927
0368187 SZ 34/2000 Austria   Start Trial PRODUCT NAME: LANTUS - INSULIN GLARGIN
0792290 PA2004005,C0792290 Lithuania   Start Trial PRODUCT NAME: INSULIN DETEMIR; REGISTRATION NO/DATE: EU/1/04/278/001, EU/1/04/278/002, EU/1/04/278/003, EU/1/04/278/004, EU/1/04/278/005, EU/1/04/278/006, EU/1/04/278/007, EU/1/04/278/008, EU/1/04/278/00 20040601
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Dow
McKesson
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.